Medicare 白内障术后滴眼液处方模式与费用分析
PURPOSE: To determine costs and prescribing patterns of postoperative eye drops for cataract surgery and estimate potential savings of generic or therapeutic drug substitutions. DESIGN: Retrospective, cross-sectional analysis.…
要点
- 品牌药占术后滴眼液处方量57.5%,贡献76.5%总费用。
- 局部抗生素处方率最高(89%),其次为激素(86%)和非甾体抗炎药(66%)。
核心结论
- 在缺乏昂贵选项临床优效性证据的情况下,使用仿制或治疗性替代可显著提升医疗价值。
研究设计与样本
- 回顾性横断面分析,使用Medicare Part D索赔数据。
主要发现
- 88%患者被处方术后滴眼液,品牌药占处方量57.5%。
- 1次和2次手术患者的平均药物费用分别为228美元和324美元。
- 局部抗生素处方率89%,激素86%,非甾体抗炎药66%,分别占总费用26%、37%、36%。
- 调整分析中,与费用增加相关的患者因素包括高龄、女性和种族或族裔;医生因素包括女性、执业年限更长、都市 vs 非都市执业、东北部 vs 南部及南部 vs 中西部执业。
关键数值与推荐
- 术后滴眼液处方率88%,品牌药占处方量57.5%。
- 1次和2次手术平均药物费用分别为228美元和324美元。
临床怎么用
- 优先选用仿制或治疗性替代药物,可在无临床优效性证据时降低术后滴眼液费用。
- 关注高龄、女性及特定执业区域等费用相关因素,优化处方选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine costs and prescribing patterns of postoperative eye drops for cataract surgery and estimate potential savings of generic or therapeutic drug substitutions. DESIGN: Retrospective, cross-sectional analysis. PARTICIPANTS: Medicare beneficiaries aged ≥65 years with Part D coverage who underwent cataract surgery in 2016. METHODS: Medicare Part D claims were used to extract information on eye drop prescriptions that were filled during the postoperative period of cataract surgery. Savings from generic or therapeutic drug substitutions were estimated for brand medications. MAIN OUTCOME MEASURES: Total cost of postoperative eye drops for cataract surgery and physician and patient factors associated with medication cost. RESULTS: Postoperative eye drops were prescribed in 2016 to 88% of 591 733 Medicare beneficiaries who underwent cataract surgery during that calendar year, with brand medications accounting for 57.5% of prescription volume. The overall cost totaled more than $167 million, 76.5% of which was attributable to use of brand medications. The mean costs of medications were $228 and $324 for those undergoing 1 and 2 surgeries, respectively. Topical antibiotics (89%) were the most commonly prescribed drug class by volume, followed by topical steroids (86%) and nonsteroidal anti-inflammatory drugs (66%), and accounted for 26%, 37%, and 36% of the total cataract surgery eye drop cost, respectively. Use of therapeutic and generic alternatives could have resulted in cost savings of as much as $118 million, or 70% of the total cost of postoperative eye drops. In adjusted analysis, patient factors associated with increased eye drop cost included older age, female gender, and race or ethnicity. Physician characteristics associated with increased eye drop cost included female gender, greater number of years in practice, practicing in metropolitan versus nonmetropolitan areas, and practicing in the Northeast versus the South and in the South versus the Midwest. CONCLUSIONS: The cost to the Centers for Medicare and Medicaid Services for eye drops prescribed for postoperative use after cataract surgery in 2016 was approximately $170 million. In the absence of evidence of clinical superiority of expensive versus less costly options, substantial opportunity exists to improve the value of care delivered to Medicare beneficiaries.
引用
- Zafar S, Wang P, Schein OD, et al. Prescribing Patterns and Costs Associated with Postoperative Eye Drop Use in Medicare Beneficiaries Undergoing Cataract Surgery. Ophthalmology. 2019. PMID: 31952884. doi:10.1016/j.ophtha.2019.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。